[11C]Yohimbine PET Study of alpha2-AR

Healthy Controls Clinical Trial

— [11C]Yohimbine  

Official title:

Positron Emission Tomography Study of alpha2-adrenergic Receptors With [11C]Yohimbine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03520543
• Other study ID #: 69HCL17_0196
• Secondary ID: 2018-000380-82
• Status: Completed
• Phase: Phase 1
• Start date: May 21, 2018
• Est. completion date: January 21, 2019

Study information

• Verified date: February 2020
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to model tissue specific kinetics of [11C]Yohimbine in healthy male participants by positron emission tomography (PET) and the appropriate arterial input function (part A) ; to determine the reproducibility of measures (classical test-retest study, part B1) and to measure the blocking of [11C]Yohimbine uptake in the brain following single oral dose administration of clonidine (part B2).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: January 21, 2019
• Est. primary completion date: July 21, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 35 Years

Eligibility

Inclusion Criteria:

• Healthy male volunteers

• Age between 20 years and 35 years

• Weight between 50kg and 90kg

• Without neurologic or psychiatric history

• Without head trauma history including loss of consciousness superior to 30 minutes.

• Affiliated to a social security or similar scheme

• Not subject to any legal protection measures

• Participant must have signed an informed consent document indicating that they understand the purpose of, and procedures required for, the study and are willing to participate in the study and comply with the study procedures and restrictions

Exclusion Criteria:

• Allen test (assessing the arterial blood flow to the hand) indicating abnormal blood supply to the hand

• Subject with orthostatic hypotension

• Subject with alcohol or substance abuses history

• Subject with somatic drug therapies

• MRI contraindications (implanted or embedded metal objects in the head or body)

• PET contraindications

• Clonidine contraindications

• Exposed to 1 millisievert or more of ionizing radiation in the year before the start of this study

• Subject unable to sign written consent for participation in the study

Related Conditions & MeSH terms

• Healthy Controls

Intervention

Drug:
• [11C]Yohimbine
Each subject will receive an intravenous (IV) bolus injection of [11C]Yohimbine at a dose of 370 MegaBecquerel (MBq) ± 10% with concomitant arterial blood sampling. The distribution of [11C]Yohimbine in brain will be measured by dynamic PET scans obtained from the time of injection for up to 90 minutes along with measurement of the tracer input function with arterial samples for intact tracer and metabolites to establish the total and regional compartmental kinetics of [11C]Yohimbine.
• [11C]Yohimbine (Part B1) and [11C]Yohimbine + clonidine (Part B2)
Part B1 : Test Retest Variability will be assessed on percent difference in the binding potential following [11C]Yohimbine PET scan (IV bolus injection of [11C]Yohimbine at a dose of 370 MBq ± 10%) obtained at least 1 week after [11C]Yohimbine PET scan of part A. Part B2 : Occupancy of alpha2-adrenergic receptors in brain by clonidine will be evaluated by comparing the binding potential of [11C]Yohimbine (IV bolus injection of [11C]Yohimbine at a dose of 370 MBq ± 10%) after single oral dose of clonidine (0,15mg) to the binding potential of [11C]Yohimbine obtained at baseline (part A).

Locations

Country	Name	City	State
France	Service de Neurologie C - Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, GHE	Bron

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Binding potentials	Binding potentials are calculated using compartmental modelling techniques	180 minutes
Secondary	Number of participants with adverse events as a measure of safety and tolerability	An adverse effect is any untoward medical events that occur in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product	Up to 7 days after part B